Exposure to extreme temperatures account for 3% of NHS healthcare costs in England, equal to £3bn, which is more than its ...

HSSIB and RCEM share widespread concern about normalising ‘corridor care’ and its impact on patients and staff across all ...

Associate Professor Viktoria Eleftheriadou discusses the launch of the UK’s first vitiligo registry as part of the VIRTUAL-UK pilot study.

Professor Thomas F. Lüscher discusses the new ESC clinical consensus statement on vaccination and its pivotal role in ...

A new analysis highlights differential long-term drug survival of commonly used biologics in psoriasis to guide treatment ...

Patients who regularly consume a healthy diet may benefit from air pollution having less impact on their lung function, a ...

Patients with psoriasis are at increased risk of developing age-related macular degeneration, new research has found.

A personalised exercise and self-management rehabilitation programme for adults living with multimorbidity is both acceptable and deliverable, according to a feasibility study, paving the way for ...

Depemokimab (brand name Exdensur) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is the first and only ultra-long-acting biologic with twice-yearly dosing to ...

Serum immunoglobulin A (IgA) is a reliable biomarker of prior respiratory syncytial virus (RSV) infection in children under two years of age, a multinational study has confirmed. Human RSV is a highly ...

Robotic-assisted bronchoscopy combined with a specialist CT scanner can reach very small tumours growing in hard-to-reach parts of the lung, offering patients the possibility of earlier lung cancer ...

The British Society for Antimicrobial Chemotherapy’s National OPAT Conference 2025 captured the evolution of OPAT in the midst of increasingly complex health service provision in the UK. As pressures ...